Sollievo Pharmaceuticals, Inc. Announces a Breakthrough in Intramuscular Sedation of Agitated and Violent Patients
Retrieved on:
Tuesday, July 5, 2022
Hospitals, Pharmaceutical, Health, Other Health, Health, FDA, Abbreviated New Drug Application, Patient, CEO, Agitation, COVID, Violence, Â, ED, Industry, Emergency department, Verbal abuse, Risk, Nursing, Absorption, Casa Sollievo della Sofferenza, Medication, Hospital, Pharmaceutical industry, Avizafone
The onset of sedation from current injectable products is unreliable, with sedation ranging from five to 45 minutes.
Key Points:
- The onset of sedation from current injectable products is unreliable, with sedation ranging from five to 45 minutes.
- Sollievo believes there is strong evidence that its proprietary formulation can more rapidly and consistently sedate aggressive patients.
- While consistent sedation must begin with consistent drug delivery, Sollievos breakthrough formulation is an invaluable advancement for an industry where every minute matters.
- An intramuscular injection capable of rapidly and consistently de-escalating violent patients would see significant usage in this challenging environment.